K-V Pharmaceutical Company 

(Public, NYSE:KV.A)   Watch this stock   
Find more results for KV.A

Key stats and ratios

Q2 (Jun '08) 2008
Net profit margin 8.42% 14.68%
Operating margin 13.79% 21.66%
EBITD margin - 26.83%
Return on average assets 5.77% 11.21%
Return on average equity 10.86% 21.43%
Employees 1,590 -

Address

2503 South Hanley Road
St. Louis, MO 63144
United States - Map
+1-314-6456600 (Phone)
+1-314-6442419 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance

K-V Pharmaceutical Company discussed on blogs

Ranking All U.S. Stocks by Weekly Performance - NASD100.com ... - Investor's Resources - NASD100.com - Daily Stock Rankings - 17 hours ago

K-V Pharmaceutical Company discussions

  View all discussions »

Description

K-V Pharmaceutical Company (KV) is a fully integrated specialty pharmaceutical company that develops, manufactures, acquires and markets branded and generic/non-branded prescription pharmaceutical products. The Company has a range of dosage form capabilities, including tablets, capsules, creams, liquids and ointments. KV conducts its branded pharmaceutical operations through Ther-Rx Corporation (Ther-Rx) and its generic/non-branded pharmaceutical operations through ETHEX Corporation (ETHEX). Through Particle Dynamics, Inc. (PDI), the Company also develops, manufactures and markets value-added raw material products for the pharmaceutical, nutritional, personal care, food and other markets. The Company has developed a variety of drug delivery and formulation technologies, which are primarily focused in four principal areas: SITE RELEASE; tastemasking; oral controlled release, and oral quick dissolving tablets.

Officers and directors

David A. Van Vliet
Interim Chief Executive Officer; President and Chief Executive Officer of ETHEX Corporation
Age: 53
Bio & Compensation - Reuters
Thomas McHugh
Interim Chief Financial Officer, Vice President - Finance, Controller
Bio & Compensation - Reuters
Patricia K. McCullough
Chief Executive Officer of ETHEX Corporation
Age: 56
Bio & Compensation - Reuters
Rita E. Bleser
President - Pharmaceutical Manufacturing Division
Age: 52
Bio & Compensation - Reuters
Gregory J. Divis Jr.
President, Ther-Rx Corporation
Age: 41
Bio & Compensation - Reuters
David S. Hermelin
Vice President - Corporate Strategy and Operations Analysis, Director
Age: 41
Bio & Compensation - Reuters
Michael S. Anderson
Corporate Vice President - Industry Presence and Development
Age: 59
Bio & Compensation - Reuters
Raymond F. Chiostri
Corporate Vice President
Age: 74
Bio & Compensation - Reuters
Paul T. Brady
Vice President - Business Development Administration
Age: 45
Bio & Compensation - Reuters
Richard H. Chibnall
Chief Accounting Officer
Age: 52
Bio & Compensation - Reuters